Mutations in people who cant sweat or feel pain may suggest medication dosages for chronic pain

Mutations in people who cant sweat or feel pain may suggest medication dosages for chronic pain ...

A study that examined gene mutations in individuals with a rare condition that stops them from sweating or feeling pain might guide the way towards identifying new drugs solutions for chronic pain patients.

Chronic pain and the opioid crisis

An incredibly rare condition

Genetic analyses from 231 patients with an extremely rare condition known as congenital insensitivity to pain with anhidrosis (CIPA) have been used by Schechtman and her team. The CIPA has affected almost one in 125 million people, which has resulted in a loss of algesia (the ability to feel pain), loss of sweat, and even increased symptoms such as developmental delay and intellectual disability.

mutations in a gene called NTRK1, which encodes an important receptor in the brain, the tropomyosin receptor kinase A (TrkA), have resulted in TrkA, which, durant the brains development, helps to develop pain-sensing neurons.

NGF and TrkA signaling improve inflammation and nerve pain in the mature brain. CIPA found the patients gene data an obvious target for the group. Mutations in TrkA may completely abolish NGF signaling, and patients with these mutations do not feel pain. Schectman suggests understanding how these different mutations affect pain signaling pathways and develop new therapeutic pathways.

According to Schechtman, previous analyses in mice that tried to broaden signing through TrKA or NGF breached barriers. [...] NGF signaling may affect neuron remodeling, causing undesirable side effects. Specifically identifying pathways mediated by NGF that lead to pain and do not affect neuron remodeling and may inhibit these pathways.

Mapping mutations

The CIPA patients genetic analysis was recreated using a simulated 3D model of TrkA. The result was found to be a total of 467 mutations across the NTRK1 gene. Many of these mutations affected a region called the kinase domain, which plays a vital role in rapiding chemical reactions.

According to previous evidence, Schechtman and his team discovered that an enzyme called phospholipase-gamma (PLC) might play a role in TrkA pain signaling. They identified that many mutations in CIPA patients interfered with the binding of TrkAs kinase domains.

Mimics disrupt a pain pathway

The group decided to employ some subterfuge to disrupt the pain pathway. They created a mimic that might trick PLC into binding with it instead of TrkA, reducing the amount of pain signaling through this protein.

The researchers explained that their decoy substance, TAT-pQYP, was effective as intended in human embryonic kidney cells and then demonstrated that mice who were given the medication showed a reduced sensitivity to inflammation.

The authors are cautious about their findings. The pathways being investigated are complex and may even play an important role in other biochemical processes that may potentially cause unexpected side effects. However, Schechtman is clear about the need to continue such research to investigate for chronic pain sufferers. Around 50% of these patients are refractory to all available drugs. She believes that deeper understanding of pain pathways may help to identify new therapeutic strategies and identify new targets.

You may also like: